Drug intelligence / Profile preview

Lactobacillus plantarum PCS 26

Development stage: Unknown
Lead developer: Pathogen Combat Project
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum PCS 26 is a specific probiotic bacterial strain originally isolated from traditional Slovenian cheese as part of the Pathogen Combat Project. It is classified as a live biotherapeutic product and has been studied for its potential health benefits, particularly in the prevention and treatment of urinary tract infections (UTIs) in children and as a dietary supplement for patients with metabolic syndrome. The strain demonstrates strong acid and bile tolerance, making it suitable for oral administration. Its mechanism of action involves modulation of the host microbiota and immunomodulatory effects that may help inhibit pathogenic bacteria such as uropathogenic Escherichia coli (UPEC). Clinical pilot studies suggest it may reduce recurrence rates of UTIs and shorten febrile periods during infection, though larger studies are needed to confirm efficacy[1][2][7][9].

Targets

UPEC (Uropathogenic Escherichia coli)

Beyond the preview

Go deeper on Lactobacillus plantarum PCS 26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus plantarum PCS 26.

Explore the full profile